NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • Bio-Neuroscience
    25 - 27 February 2025
    Amsterdam

    download

  • 18th Annual European Life Sciences CEO Forum
    26 - 27 February 2025
    Zurich

    download

  • Redefining Early Stage of Investment (RESI)
    1 April 2025
    Barcelona

    download
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights<
25 Mar 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Cash Position Expected to Support Operations into 2H 2026
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET<
25 Mar 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress<
24 Mar 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock<
18 Mar 2025

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Aggregate gross proceeds to Mineralys from the offering were approximately $201.2M
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease<
13 Mar 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology<
11 Mar 2025

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology

Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock<
11 Mar 2025

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Underwritten public offering of $250.0 million of shares of its common stock
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension<
10 Mar 2025

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trial
NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology<
06 Mar 2025

NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology

Positive results support advancement of icosabutate into further clinical development in MASH patients
MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity<
05 Mar 2025

MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity

Significant advancement toward more precise, safer, and more effective treatments for patients.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs.